Archives of Virology

, Volume 78, Issue 1–2, pp 9–18 | Cite as

The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection

  • R. H. Kimberlin
  • Carol A. Walker
Original Papers


The effects of up to 12 daily doses of HPA-23 (ammonium 5-tungsto-2-antimoniate) on scrapie were studied using five experimental models of the disease, some with widely different incubation times. Treatment of animals with HPA-23, starting just before injecting scrapie, produced survivors. In some experiments, animals were fully protected against several hundred infectious units of scrapie. Treatment of animals after infection was far less effective. Prolonging the treatment for several weeks was no more effective than treating for a few days. In a very long incubation model of scrapie, the course of 12 daily doses of HPA-23 represented less than 3 per cent of the total incubation period. HPA-23 may interact with certain cells of the lymphoreticular system, preventing infection and, perhaps, the early replication of agent.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bernouilli, C., Siegfried, J., Baumgartner, G., Regli, F., Rabinowicz, T., Gadjusek, D. C., Gibbs, C. J., Jr.: Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lanceti, 478–479 (1977).Google Scholar
  2. 2.
    Bountiff, L.: Ph. D. Thesis, University of Reading, U.K., 1982.Google Scholar
  3. 3.
    Braham, J.: Jakob-Creutzfeldt disease: treatment by amantidine. Brit. Med. J.4, 212–213 (1971).Google Scholar
  4. 4.
    Chermann, J. C., Dormont, D.: Unpublished results.Google Scholar
  5. 5.
    Chermann, J. C., Sinoussi, F. C., Jasmin, C.: Inhibition of RNA-dependent DNA polymerase of murine oncornaviruses by ammonium-5-tungsto-antimoniate. Biochem. Biophys. Res. Commun.65, 1229–1236 (1975).Google Scholar
  6. 6.
    Dickinson, A. G.: Unpublished results.Google Scholar
  7. 7.
    Dickinson, A. G., Fraser, H.: An assessment of the genetics of scrapie in sheep and mice. In:Prusiner, S. B., Hadlow, W. J. (eds.), Slow Transmissible Diseases of the Nervous System, Vol. 1, 367–385. New York: Academic Press 1979.Google Scholar
  8. 8.
    Dickinnso, A. G., Fraser, H., McConnell, I., Outram, G. W.: Mitogenic stimulation of the host enhances susceptibility to scrapie. Nature272, 54–55 (1978).Google Scholar
  9. 9.
    Duffy, P., Wolf, J., Collins, G., de Voe, A. G., Streeten, B., Cowen, D.: Possible person-to-person transmission of Creutzfeldt-Jakob disease. New Engl. J. Med.290, 692–693 (1974).Google Scholar
  10. 10.
    Herishanu, Y.: Antiviral drugs in Jakob-Creutzfeldt disease. J. Am. Geriat. Soc.21, 229–231 (1973).Google Scholar
  11. 11.
    Jasmin, C., Chermann, J. C., Herve, G., Teze, A., Souchay, P., Boy-Loustau, C., Raybaud, N., Sinoussi, F., Raynaud, M.:In vivo inhibition of murine leukaemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimoniate. J. Natl. Cancer Inst.53, 469–474 (1974).Google Scholar
  12. 12.
    Jasmin, C., Chermann, J. C., Raynaud, M., Wener, G., Raybaud, N., Sinnoussi, F., Boy-Loustau, C.:In vivo andin vitro antiviral activity of the mineral condensed heteropolyanion 5-tungsto-2-antimoniate. In:Daikos, G. K. (ed.), Proceedings of the 8th International Congress of Chemotherapy, Vol. 2, 956–962. Urban und Schwarzenberg 1974.Google Scholar
  13. 13.
    Kimberlin, R. H.: Discovery of treatments that enhance or suppress scrapie infection. J. Supramolec. Struc. Suppl.2, 275 (1978).Google Scholar
  14. 14.
    Kimberlin, R. H.: Scrapie as a model slow virus disease: problems, progress and diagnosis. In:Kurstak, E., Kurstak, C. (eds.), Comparative Diagnosis of Viral Diseases, Vol. 3A, 349–390. New York: Academic Press 1981.Google Scholar
  15. 15.
    Kimberlin, R. H., Cunnington, P. G.: Reduction of scrapie incubation time in mice and hamsters by a single injection of methanol extraction residue of BCG. FEMS Microbiol. Letts.3, 169–172 (1978).Google Scholar
  16. 16.
    Kimberlin, R. H., Walker, C. A.: Pathogenesis of mouse scrapie: effect of route of inoculation on infectivity titres and dose-response curves. J. comp. Pathol.88, 39–47 (1978).Google Scholar
  17. 17.
    Kimberlin, R. H., Walker, C. A.: Antiviral compound effective against experimental scrapie. Lancetii, 591–592 (1979).Google Scholar
  18. 18.
    Kimberlin, R. H., Walker, C. A.: Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. J. comp. Pathol.89, 551–562 (1979).Google Scholar
  19. 19.
    Kimberlin, R. H., Walker, C. A.: Pathogenesis of mouse scrapie: evidence for neural spread of infection to the CNS. J. gen. Virol.51, 183–187 (1980).Google Scholar
  20. 20.
    Kimberlin, R. H., Walker, C. A.: Invasion of the CNS by scrapie agent and its spread to different parts of the brain. In:Court, L. (ed.), Virus Non Conventionnels et Affections du Système Nerveaux Central, 15–33. Paris: Masson 1983.Google Scholar
  21. 21.
    Kimberlin, R. H., Walker, C. A.: Unpublished results.Google Scholar
  22. 22.
    Larnicol, N., Augery, Y., Ne Bousse-Kerdiles, C., Degiorgis, V., Chermann, J. C., Teze, A., Jasmin, C.:In vivo effect of a new mineral condensed ion (HPA39) on murine Friend leukaemia. J. gen. Virol.55, 17–23 (1981).Google Scholar
  23. 23.
    Marsh, R. F.: Effect of vaccinia-activated macrophages on scrapie infection in hamsters. In:Streilein, J. W., Hart, D. A., Stein-Streilein, J., Duncan, W. R., Billingham, R. E. (eds.), Hamster Immune Response in Infectious and Oncologic Diseases, 359–363. New York: Plenum 1981.Google Scholar
  24. 24.
    Parker, R. C.: Methods of Tissue Culture, 245–266. London: Pitman 1961.Google Scholar
  25. 25.
    Sanders, W. L.: Creutzfeldt-Jakob disease treated with amantidine. J. Neurol. Neurosurg. Psychiatry42, 960–961 (1979).Google Scholar
  26. 26.
    Sanders, W. C., Dunn, T. L.: Creutzfeldt-Jakob disease treated with amantidine. J. Neurol. Neurosurg. Psychiatry36, 581–584 (1973).Google Scholar
  27. 27.
    Tateishi, J.: Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice. J. Neurol. Neurosurg. Psychiatry44, 723–724 (1981).Google Scholar
  28. 28.
    Tsiang, H., Atanasiu, P., Chermann, J. C., Jasmin, C.: Inhibition of rabies virusin vitro by the ammonium-5-tungsto-2-antimoniate. J. gen. Virol.40, 665–668 (1978).Google Scholar
  29. 29.
    Werner, G. H., Jasmin, C., Chermann, J. C.: Effect of ammonium 5-tungsto-2-antimoniate on encephalomyocarditis and vesicular stomatitis virus infections in mice. J. gen. Virol.31, 59–64 (1976).Google Scholar
  30. 30.
    Will, R. G., Matthews, W. B.: Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry45, 235–238 (1982).Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • R. H. Kimberlin
    • 1
    • 2
  • Carol A. Walker
    • 1
  1. 1.A.R.C. Institute for Research on Animal Diseases, ComptonNewburyUnited Kingdom
  2. 2.A.R.C. and M.R.C. Neuropathogenesis UnitEdinburghUK

Personalised recommendations